1. Home
  2. AMPS vs OMER Comparison

AMPS vs OMER Comparison

Compare AMPS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMPS
  • OMER
  • Stock Information
  • Founded
  • AMPS 2009
  • OMER 1994
  • Country
  • AMPS United States
  • OMER United States
  • Employees
  • AMPS N/A
  • OMER N/A
  • Industry
  • AMPS Electric Utilities: Central
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMPS Utilities
  • OMER Health Care
  • Exchange
  • AMPS Nasdaq
  • OMER Nasdaq
  • Market Cap
  • AMPS 608.0M
  • OMER 579.5M
  • IPO Year
  • AMPS N/A
  • OMER 2009
  • Fundamental
  • Price
  • AMPS $3.82
  • OMER $9.33
  • Analyst Decision
  • AMPS Strong Buy
  • OMER Buy
  • Analyst Count
  • AMPS 9
  • OMER 4
  • Target Price
  • AMPS $5.38
  • OMER $22.50
  • AVG Volume (30 Days)
  • AMPS 1.4M
  • OMER 1.1M
  • Earning Date
  • AMPS 03-13-2025
  • OMER 11-13-2024
  • Dividend Yield
  • AMPS N/A
  • OMER N/A
  • EPS Growth
  • AMPS N/A
  • OMER N/A
  • EPS
  • AMPS 0.22
  • OMER N/A
  • Revenue
  • AMPS $185,992,000.00
  • OMER N/A
  • Revenue This Year
  • AMPS $30.56
  • OMER N/A
  • Revenue Next Year
  • AMPS $17.93
  • OMER N/A
  • P/E Ratio
  • AMPS $17.30
  • OMER N/A
  • Revenue Growth
  • AMPS 25.90
  • OMER N/A
  • 52 Week Low
  • AMPS $2.71
  • OMER $2.61
  • 52 Week High
  • AMPS $7.28
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • AMPS 43.69
  • OMER 49.55
  • Support Level
  • AMPS $3.82
  • OMER $8.21
  • Resistance Level
  • AMPS $4.24
  • OMER $11.26
  • Average True Range (ATR)
  • AMPS 0.24
  • OMER 0.93
  • MACD
  • AMPS -0.06
  • OMER -0.20
  • Stochastic Oscillator
  • AMPS 4.64
  • OMER 31.37

About AMPS Altus Power Inc.

Altus Power Inc is a developer, owner, and operator of large-scale photovoltaic and energy storage systems across the United States. The company serve commercial, industrial, public sector, and community solar customers. Its mission is to drive the clean energy transition by developing and operating solar generation and energy storage facilities. It owns a diverse portfolio of solar PV systems and has long-term agreements with enterprise entities and residential customers. Their primary product offerings include leases and revenue contracts for solar power generation, alongside electric vehicle charging and energy storage solutions. Revenue streams include power purchase agreements, net metering credit agreements, and SREC revenue.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: